All Articles

Steve Cohen is The Latest Billionaire to Bet on This Small Biotech

October 5, 2023
x min read

Wall Street hedge fund manager Steve Cohen has taken another big stake in a small publicly traded biotech company.

What’s happening:

Why it matters:

  • Bionomics recently released positive clinical trial data for their novel therapeutic BNC210 which is a treatment for PTSD

The intrigue:

By the numbers:

  • Steve Cohen’s hedge fund Point72 now owns roughly 8.1% of the outstanding shares of Bionomics
  • Currently, the market capitalization of Bionomics is approximately $30 million

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.